NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR
申请人:TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES
公开号:US20160304459A1
公开(公告)日:2016-10-20
[Problems] To provide a novel peptide synthesis technique that is completely different than heretofore, and to provide a novel compound that enables the synthesis/creation of a novel artificial functional protein and the synthesis/creation of a novel functional peptide, as well as a method for producing the same. [Solution] A compound represented by formula (I) or a salt thereof.
Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U-purinoceptors
作者:Eduardo R. Lazarowski、William C. Watt、M. Jackson Stutts、H. Alex Brown、Richard C. Boucher、T. Kendall Harden
DOI:10.1111/j.1476-5381.1996.tb15175.x
日期:1996.1
secretory pathway that is activated by extracellular nucleotides, e.g. uridine-5'triphosphate (UTP), acting on P2U purinoceptors. Since UTP is susceptible to hydrolysis by nucleotidases and phosphatases present in the airways, the identification of stable P2U-purinoceptor agonists would be of therapeutic relevance. 2. Uridine-5'-O-(3-thiotriphosphate) (UTP gamma S) was synthesized by nucleoside diphosphate
A chromium complex for use in treating metabolic disorders, particularly Type 1 and Type 2 diabetes.
一种铬配合物,用于治疗代谢紊乱,特别是1型和2型糖尿病。
Primer, primer set, and nucleic acid amplification method and mutation detection method using the same
申请人:Hayashizaki Yoshihide
公开号:US20080227104A1
公开(公告)日:2008-09-18
The present invention provides a primer that effectively can detect, for example, the double helix structure of a nucleic acid. The primer is a labeled nucleic acid containing at least one structure represented by the following formula (16),
where B is an atomic group having a nucleobase skeleton, E is an atomic group having a deoxyribose skeleton, a ribose skeleton, or a structure derived from either one of them, or an atomic group having a peptide structure or a peptoid structure, and Z
11
and Z
12
are each an atomic group that exhibits fluorescence and are identical to or different from each other.
Methods to generate analogs of coenzyme A in vitro and in vivo are disclosed. The methods comprise reacting pantetheine or a derivative thereof with a reporter to form labeled pantetheine or a derivative thereof, phosphorylating the labeled pantetheine or derivative thereof to form phosphopantetheine or a derivative thereof, adenylating the labeled phosphopantetheine or derivative thereof to form a labeled dephosphoCoenzyme A or derivative thereof, and phosphorylating the 3′-hydrozyl of the labeled dephosphoCoenzume A or derivative thereof to form a labeled coenzyme A analog or derivative thereof.